Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono appoints chief medical officer

Steven Hildemann joins from Merck & Co
Merck Steven Hildemann

Dr Steven Hildemann has left the US-based Merck & Co to join its German namesake Merck KGaA as chief medical officer of its pharma business Merck Serono.

Dr Hildemann had been in his most recent role with Merck & Co – known as MSD outside the US – for just over a year, serving as associate VP of global clinical trial operations in Europe holding responsibility for the execution of development programmes across the region.

Prior to this role, he served as senior director of global clinical trial operations Europe.

He joined Merck & Co after the US pharma giant merger with his former company, Schering-Plough, in 2009. He had previously served as global project leader at Schering-Plough following a spell as medical director for the company's operations in Germany.

His other former roles include working as a medical director for Amgen in Germany and as a senior global medical director cardiovascular for Pharmacia, and then later Pfizer after its takeover of the company in 2002.

As Merck Serono's chief medical officer Dr Hildemann succeeds Dr Florian Bieber who left to “pursue other opportunities” according to the company.

He joins shortly after Merck Serono announced a new CEO in the form of former chief operating officer Belén Garijo, who is tasked with leading the company at a time of major restructuring.

Dr Hildemann will report to Merck Serono's global head of R&D Dr Annalisa Jenkins, who commented that Dr Hildemann's experience was “very impressive”.

“His patient-centred focus is well-aligned with our commitment to delivering differentiated new medicines to people living with unmet medical needs around the world,” said Dr Jenkins.

15th January 2014

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics